Elie Dolgin’s recent article in Nature Biotechnology explains why the apparent failure of the first senolytic drug to enter clinical trials is far from being a refutation of the senolytic hypothesis, and reviews the growing arsenal of other senolytics currently in development – including work by SRF’s Dr. Amit Sharma and SRF-supported startup Oisín Biotechnologies.
Send In The Senolytics
- By SRF
- November 17, 2020
- 9:50 am
Elie Dolgin's recent article in Nature Biotechnology explains why the failure of the first senolytic drug to enter clinical trials is far from being a refutation of the senolytic hypothesis, and reviews the growing arsenal of other senolytics currently in development - including work by SRF's Dr. Amit Sharma and SRF-supported startup Oisín Biotechnologies.

- By SRF
- November 17, 2020
- 9:50 am
Recent Posts:
Announcing the Biomarkers of Aging Consortium
SRF March 10, 2023 12:56 pm
Action at the Governmental Level for Longevity
SRF March 10, 2023 12:30 pm
Scenes from the Lab
SRF March 8, 2023 5:16 pm
A Busy Spring in the Education Department
SRF March 8, 2023 4:22 pm
New Peer-Reviewed Paper from SENS Research Foundation: Iron Homeostasis as a Senolytic Target
SRF February 8, 2023 5:47 pm
Announcement: Amicable Settlement of Donor Dispute
SRF October 28, 2022 3:34 pm
The Zombie Problem Happening Inside You
Maria Entraigues Abramson September 9, 2022 7:50 pm
Announcing the new Chairman of the SRF Board of Directors
SRF May 9, 2022 5:57 pm
A Message from the SRF Board of Directors
SRF April 15, 2022 8:11 pm
New Peer-Reviewed Paper from SENS Research Foundation Reports a Better Method to Study How Immune Cells Seek and Destroy Senescent Cells
Michael Rae April 12, 2022 2:02 am
We are thrilled to announce the expansion of our Research Center
SRF April 1, 2022 11:25 pm